Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Trial number:
NCT04248829
Trial phase:
3
Study type:
Targeted therapy
Overall status:
Active, not recruiting

Study start date

February, 2020

Scientific title

A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Summary

This Phase III study will be conducted to evaluate the efficacy and safety of YH25448 as first-line treatment in locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) patients with EGFR mutations

Pathologically confirmed adenocarcinoma of the lungLocally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy At least 1 of the 2 common EGFR mutations known to be associated with EGFR TKI sensitivity (Ex19del or L858R), either alone or in combination with other EGFR mutations Treatment-naïve for locally advanced or metastatic NSCLC WHO performance status score of 0 to 1 with no clinically significant deterioration over the previous 2 weeks before randomization At least 1 measurable lesion, not previously irradiated and not chosen for biopsy during the study Screening period

Study design

Primary purpose: Treatment, Allocation: Randomized, Intervention model: Parallel Assignment, Intervention model description: Approximately 380 patients will be randomized in a 1:1 ratio to either lazertinib (n=190) or gefitinib (n= 190)., , Following objective disease progression according to RECIST v1.1, as per investigator assessment, patients who were randomized to gefitinib arm may have the option to receive open-label lazertinib , Masking: Quadruple, Subject masked: Yes, Caregiver masked: Yes, Investigator masked: Yes, Outcomes assessor masked: Yes,

Conditions

Non-Small Cell Lung Cancer

Other study ID numbers

YH25448-301

Choose trial site (126)